Background: Monoclonal antibodies (mAbs) targeting immune checkpoint molecules such as programmed death ligand 1 (PD-L1), which is expressed in both immune and tumour cells, are conventional immunotherapy approaches. Although app... ...

请注册登录后继续浏览